Navigation Links
MAP Pharmaceuticals Announces Phase 3 Study of Unit Dose Budesonide in Children With Asthma Did Not Meet Primary Endpoints
Date:2/23/2009

steroid naïve children with asthma, 12-months to eight years of age, were randomized to receive 0.25mg UDB, 0.135mg UDB or placebo twice a day over a 12-week period. The co-primary endpoints evaluated asthma control as assessed by changes from baseline as compared to placebo in nighttime composite symptom scores, and daytime composite symptom scores, both comprised of cough, wheeze and shortness of breath.

Conference Call Details

MAP Pharmaceuticals management will host a conference call at 5:30 p.m. ET today to discuss these results.

You may join the call via telephone at 888-631-5931 (domestic) or 913-312-4375 (international). Access to the live webcast will be available via the Investor Relations section of the Company's Website at http://www.mappharma.com. A replay will also be available within 24 hours for at least seven days following the conference call.

About MAP Pharmaceuticals

MAP Pharmaceuticals is dedicated to developing and commercializing new therapies for children and adults suffering from chronic conditions that are not adequately treated by currently available medicines. The company has two product candidates in Phase 3 clinical development. Unit Dose Budesonide is being developed in collaboration with AstraZeneca for the potential treatment of asthma in children, and MAP0004 is being developed for the potential treatment of migraine. In addition, MAP Pharmaceuticals generates new pipeline opportunities by applying its proprietary drug particle and inhalation technologies to enhance the therapeutic benefits of proven drugs, while minimizing risk, by capitalizing on their known safety, efficacy and commercialization history.

Additional information about MAP Pharmaceuticals can be found at http://www.mappharma.com.

Abou
'/>"/>

SOURCE MAP Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. AstraZenecas Partner, MAP Pharmaceuticals, Announces Phase 3 Study of Unit Dose Budesonide in Children with Asthma Did Not Meet Primary Endpoints
2. Shareholder Class Action Filed Against Rigel Pharmaceuticals, Inc. by the Law Firm of Barroway Topaz Kessler Meltzer & Check, LLP
3. Access Licenses ProLindac(TM) and MuGard(TM) to JCOM Ltd, an Affiliate of DONG-A Pharmaceuticals in Korea
4. Inspiration Biopharmaceuticals, Inc. Initiates Phase 1 Clinical Trial of IB1001 for the Treatment of Hemophilia B
5. Endo Pharmaceuticals Announces Research Collaborations to Develop Novel Pain Treatments and Discover Potential Cancer Treatments
6. Sequoia Pharmaceuticals Presents Proof of Clinical Concept of SPI-452, a Novel Pharmacokinetic Enhancer
7. Indevus Pharmaceuticals Announces PRO 2000 Found to Show Promise in Large HIV Prevention Study
8. Idenix Pharmaceuticals and GlaxoSmithKline Sign Worldwide License Agreement for IDX899, a Novel NNRTI for the Treatment of HIV
9. Raptor Pharmaceuticals Announces Completion of Patient Enrollment in Phase 2a Clinical Trial in Non-Alcoholic Steatohepatitis (NASH)
10. Oramed Pharmaceuticals Completes Proof of Concept Study of Insulin Suppository
11. Alseres Pharmaceuticals Completes Enrollment in First Stage of the Altropane(R) POET-2 Phase III Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... 2014 Professional Compounding Centers of America ... awarding the three best scientific presentations at the ... . The Formulating Better Medicines for Children ... Athens, Greece , includes dozens of ... from which three winners will be selected by ...
(Date:8/21/2014)... PARK, Calif. , Aug. 21, 2014 ... in the emerging field of regenerative medicine, announced today ... Ricciardi to the Company,s newly expanded Board of Directors. ... comprises eight directors, three of whom are independent. ... of experience working with emerging growth companies. He is ...
(Date:8/20/2014)... , Aug. 20, 2014 The National ... the latest results achieved by the real-time, pseudoephedrine ... the National Precursor Log Exchange (NPLEx), automatically blocks ... track down meth offenders and make arrests. Data ... Kansas blocked the sale of ...
Breaking Medicine Technology:Professional Compounding Centers of America will award top poster-session winners at European Paediatric Formulation Initiative in Athens 2Asterias Biotherapeutics Appoints Two Independent Directors and Announces Completion of Series A Common Stock Distribution 2Asterias Biotherapeutics Appoints Two Independent Directors and Announces Completion of Series A Common Stock Distribution 3Asterias Biotherapeutics Appoints Two Independent Directors and Announces Completion of Series A Common Stock Distribution 4Kansas's Stop-Sale System Achieves Significant Results In Battle Against Meth 2
(Date:8/21/2014)... 21, 2014 The City of Garden ... entertainment and programming for its inaugural “Re:Imagine Garden Grove ... 12, 2014, from 11 a.m. to 4 p.m., 2.85-miles ... cars and the downtown will be filled with diverse ... Community Arts Resources (CARS), for all to enjoy. , ...
(Date:8/21/2014)... Aug. 21, 2014 (HealthDay News) -- Among seniors, dimming ... The study involved more than 2,500 people, aged 65 ... study and again two, six and eight years later. ... the person,s risk of death during the study period, the ... effect, researchers led by Sharon Christ of Purdue University in ...
(Date:8/21/2014)... 21, 2014 A new study published ... increase in disability associated with speech problems from 2001-02 ... than 15% increase in disability associated with hearing problems. ... rising numbers of children who are experiencing communication disorders, ... , On a broader level, the new study, ...
(Date:8/21/2014)... Aug. 21, 2014 Researchers in the United Kingdom ... can quickly and accurately diagnose a number of rare ... study published online today in Ophthalmology , ... Using a single test, doctors were able to tailor ... mutations reducing the time and money spent on diagnosis ...
(Date:8/21/2014)... The report "Industrial Flue Gas Treatment Systems & ... Particulate Control, Mercury Control) by Application (Power Generation, ... Global Trends & Forecasts to 2019" defines and ... & services market with analysis and projection of ... The industrial flue gas treatment systems & services ...
Breaking Medicine News(10 mins):Health News:"Re:Imagine Garden Grove - A Downtown Open Streets Event" 2Health News:"Re:Imagine Garden Grove - A Downtown Open Streets Event" 3Health News:"Re:Imagine Garden Grove - A Downtown Open Streets Event" 4Health News:Failing Vision Tied to Shorter Lifespans for Seniors 2Health News:New Pediatrics Study Reveals Dramatic Increase in Speech Problems in Children Over Past Decade 2Health News:New Pediatrics Study Reveals Dramatic Increase in Speech Problems in Children Over Past Decade 3Health News:New DNA test for diagnosing diseases linked to childhood blindness 2Health News:Industrial Flue Gas Treatment Systems Market Estimated to Worth $59, 546.7 Million by 2019 – Report by MarketsandMarkets 2Health News:Industrial Flue Gas Treatment Systems Market Estimated to Worth $59, 546.7 Million by 2019 – Report by MarketsandMarkets 3Health News:Industrial Flue Gas Treatment Systems Market Estimated to Worth $59, 546.7 Million by 2019 – Report by MarketsandMarkets 4
... Gardner HealthDay Reporter , TUESDAY, Nov. 23 (HealthDay News) ... by almost 44 percent in those at highest risk for contracting ... new study finds. The reduction in risk climbed to nearly ... 90 percent of the time, the researchers added. Truvada is ...
... (CSCs), the aggressive cells thought to be resistant to current ... via a pathway that mirrors normal stem cell development. Disrupting ... breast CSCs, a finding that suggests a new drug therapy ... Proceedings of the National Academy of Sciences (PNAS) ...
... HealthDay Reporter , TUESDAY, Nov. 23 (HealthDay News) -- Being ... on a child,s IQ and ability to pay attention, new research ... (40 weeks) to those born between 34 to 36 weeks ... more than twice the risk of having an IQ score below ...
... By Amanda Gardner HealthDay Reporter , MONDAY, ... who are overweight actually perceive themselves as being normal weight, ... body weight actually fret that they,re too fat, according to ... to be often correlated with race: Black and Hispanic women ...
... Engineers have developed a new type of microchip muscle stimulator ... paralysed leg muscles. It is the first time ... is small enough to be implanted into the spinal canal ... The implant is the size of a child,s fingernail. ...
... their vision with perceptual training, according to a study from ... implications for the health and mobility of senior citizens. ... early stages of visual processing," appears in the current online ... funded by a $3.5 million grant from the National Institute ...
Cached Medicine News:Health News:Daily Pill Lowers Odds for Infection With HIV 2Health News:Daily Pill Lowers Odds for Infection With HIV 3Health News:Daily Pill Lowers Odds for Infection With HIV 4Health News:Discovery halts breast cancer stem cells 2Health News: Children Born 'Late Pre-Term' More Prone to Low IQ 2Health News: Children Born 'Late Pre-Term' More Prone to Low IQ 3Health News:1 in 4 Overweight Women Think They're Normal Size: Study 2Health News:1 in 4 Overweight Women Think They're Normal Size: Study 3Health News:New spinal implant will help people with paraplegia to exercise paralyzed limbs 2Health News:Perceptual training improves vision of the elderly 2